2024 Life Sciences Symposium

Are you ready to share your research with us?

We are bringing back the annual Huck Life Sciences Symposium for the 8th year! This FREE event provides a forum for life science researchers and is open to students, post-doctoral fellows, faculty, staff, facilities, and organizations. Since 2015, this event organized by the Huck Graduate Student Advisory Committee has brought together hundreds of researchers from diverse scientific fields, promoting interdisciplinary collaboration and networking. Register for the symposium to learn about some cool science and network with other life scientists!

Sign-up for the 2024 Life Sciences Symposium here by May 17th for registration with breakfast, lunch, dinner, and coffee.

Check out the 2024 LSS schedule click HERE! and the abstract booklet HERE

The Life Sciences Symposium will feature:

Keynote talk and panel (P.S., our theme this year is Artificial intelligence in the life sciences)
Graduate student and postdoc talks
Student poster presentations
Breaking into academia and industry workshops
Networking opportunities
and more!

Workshops

Utilizing Adobe Express to create GenAI graphics:

The Media Commons team will hold an interactive workshop to enhance many of your multimedia design needs, from crafting compelling infographics and posters to generating engaging content for social media platforms. We'll dive into the mind-blowing affordances of Adobe Firefly, exploring its role in creating GenAI graphics, seamless background fills, and distinctive fonts, enhancing the visual appeal of your projects.

To RSVP for this workshop click HERE

Keynote Speaker

Anthony Gitter is an Associate Professor in the Department of Biostatistics and Medical Informatics at the University of Wisconsin-Madison and the Jeanne M. Rowe Chair at the Morgridge Institute for Research. His research group develops machine learning tools for biochemistry applications such as drug discovery and protein engineering. In addition, they use network modeling to connect genomic, transcriptomic, and proteomic data and provide a cohesive view of a biological process, with special emphasis on virology and oncology.

Panel

Panelists Anthony Gitter, Sharon X. Huang, and David Hughes will discuss the use of AI in life sciences research.

Career Seminar

The career seminar will feature Diane Bouis and Ted Liberti.

Diane Bouis, PhD MBA (She/Her)

Diane is the outgoing Program Director for MedTech Innovator, the largest Medtech accelerator in the world and an advisor and investor to female led-biomedical startups.She has extensive experience managing startup portfolios through previous roles as Innovation Manager at the University of Michigan’s Innovation Partnerships Startup Incubator and as an innovation consultant with The Inovo Group.She has lived and worked on three continents, speaks six languages, holds a PhD on gene therapy in oncology from the University of Groningen, Netherlands and an MBA from the University of Michigan Ross School of Business.

To learn more about Diane visit Linkedin

Ted L. Liberti, CCO, Co-Founder, BioMagnetic Solution

Ted co-founded BioMagnetic Solutions (BioMag) in 2012 and has served as BioMag's COO, CEO, CBO, CCO and EVP of Business Development, managing BioMag's operations, business development and corporate partnering initiatives for BioMag's cell selection technologies and cell therapy platforms.

He is an expert on magnetic cell selection and the manufacture and optimizations of BioMag's core technology - nanomagnetic Ferrofluids for biological and cell separations. In 2021, after 11 years of R&D, BioMag completed a private-equity deal with KKR-backed Gamma Biosciences to bring BioMagnetic Solutions' FerroSelect™ Array cell selection system to market. BioMag's FerroSelect™ Array system leverages BioMag's key scientific superpower - Ferrofluids. Ferrofluids are nanomagnetic liquids (magnetic particles/beads) for bioseparations for selecting: cells, DNA, proteins, exosomes, circulating tumor cells**, rare cells & more). BioMag's FerroSelect™ cell selection system provides immunomagnetic selection for the manufacture of CAR-T cell & gene therapy (CGT) products. FerroSelect™ provides CDMOs and CAR-T groups a true path to GMP CAR-T cell manufacture in the clinic. BioMag's FerroSelect™ Array cell selection system is an automated immunomagnetic system driven by BioMag's universal "Common Capture" Ferrofluids and uses a 2-step indirect mAb labeling process for process development (PD) and GMP CAR-T product manufacture.

Ted co-founded BioMag with the acclaimed scientist and inventor Paul A. Liberti, PhD. BioMag is the successor to Immunicon Corp. (NASDAQ: IMMC) where Liberti developed CELLSEARCH® ** ~ the only FDA-approved circulating tumor cell (CTC) assay marketed & owned by J&J's Janssen unit & acquired by Menarini’s Silicon BioSystems in 2018.

Ted holds a B.S. from The Pennsylvania State University and an M.A. in Applied Economics from the University of Delaware. He completed doctoral research in economics, strategy, networks and entrepreneurship at Penn State’s Smeal College of Business and holds an MBA in international corporate strategy from the University of Delaware with high honors. Fluent in French, he started his career in international banking with JP Morgan Paris, leveraging his economics, finance, and language skills in investment banking. Later with Immunicon Corp., he assisted with business development, business strategy, contract research projects, and collaborations with bioMérieux S.A., Guerbet S.A., and French academic groups in Paris and Lyon. Ted advised on the valuation of Immunicon’s MRI contrast agent patents, leading to a $1M licensing arrangement with Sweden’s Nycomed Pharmaceuticals. From 2006 to 2012, he worked with Ben Franklin Technology Partners’ portfolio of life science, medical device, IT, and industrial firms. His career passions are: science, helping to solve extremely thorny scientific problems and building world-class biotech biotech companies that change and inflect human health with powerful technologies.

To learn more about Ted, visit Linkedin